Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269301 | 0.93 | S1PR1 (0.35) | KMT2APIK3CDPOLBS1PR1S1PR3 | |
| SCHEMBL30983500 | 0.93 | CNR1 (0.35) | KMT2APIK3CDS1PR1S1PR3S1PR5 | |
| SCHEMBL30983474 | 0.93 | CNR1 (0.35) | KMT2APIK3CDS1PR1S1PR3S1PR5 | |
| SCHEMBL30983374 | 0.93 | CNR1 (0.35) | KMT2APIK3CDS1PR1S1PR3S1PR5 | |
| SCHEMBL31268989 | 0.92 | S1PR1 (0.40) | KMT2APIK3CDS1PR1PIM1PDGFRA | |
| SCHEMBL31268742 | 0.92 | S1PR1 (0.40) | KMT2APIK3CDS1PR1PIM1PDGFRA | |
| SCHEMBL31269306 | 0.91 | PIK3CD (0.32) | KMT2APIK3CDPOLBS1PR1S1PR3 | |
| SCHEMBL31269322 | 0.91 | PPARG (0.37) | KMT2APIK3CDTLR7 | |
| SCHEMBL31268767 | 0.91 | PPARG (0.37) | KMT2APIK3CDTLR7 | |
| SCHEMBL31269103 | 0.91 | ALOX5AP (0.33) | KMT2APIK3CDS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |